| Objective:To observe the difference in clinical efficacy and safety of Yiyuan Tongluo prescription combined with thermosensitive moxibustion in the treatment of bone metastasis pain of kidney deficiency and blood stasis type tumor and Oxycodone hydrochloride sustained release tablets.Methods:Sixty patients with bone metastatic pain were randomly divided into control group and treatment group.the experimental group received Oxycodone Hydrochloride Sustained Release Tablets.The treatment group all taken Yiyuan Tongluo prescription and oxycodone hydrochloride sustained release tablets,at the same time used Heat-sensitive Moxibustion.The changes before and after analgesic treatment in 2 groups were observed,including numerical rating scale(NRS),Karnofsky(KPS),Quality of life measurement scale(EORTC QLQ C30)and WHO standards for grading acute and subacute toxic reactions.After statistical treatment,the efficacy was evaluated.Results:1.Before treatment,the two groups were compared in gender,age,disease type,pain course,metastatic site,pain site,the analgesic drug usage,pain intensity and Karlscher score,all P>0.05,the difference was not statistically significant and was comparable.2.Compare the degree of pain relief,two groups of patients after treatment of NRS score significantly lower than before treatment.The total response rate was 90.00%(27 cases)in the experimental group and 93.33%(28cases)in the treatment group.Total remission rate similar between the two groups has no statistical significance(P>0.05).3.The onset time and duration of analgesia were compared between the two groups.The onset time of analgesia was 83.33±8.84 min in the experimental group and 52.33±10.40 min in the treatment group,and statistically significant difference between the two groups(~at=12.439,p=0.000,P<0.05).The duration of the experimental group was 65.67±50.29 minutes,and that of the treatment group was 741.33±54.76 minutes.Statistically significant difference between the two groups(~bt=-7.048,p=0.000,P<0.05).4.Compare two groups of patients with functional status improvement(Karlschmidt score).After treatment,there were 18 cases in the experimental group(total effective rate 60%)and 27 cases in the treatment group(total effective rate 90.00%).Statistically significant difference between the two groups(P<0.05).5.Comparison of quality of life between the two groups(EORTC QLQ-330).After treatment,two groups of patients’physical function,social function,emotional function,fatigue,pain were improved significantly(P<0.05);The role function,cognitive function,sleep,breathing difficulties,diarrhoea and economic difficulties had no significant effect(P>0.05);Compared with the experimental group,the treatment group had obvious advantages in the symptom of nausea,vomiting,pain,decreased appetite and constipation(P<0.05).6.Comparison of WHO standards for grading acute and subacute toxic reactions between the two groups.After treatment,the treatment group of patients with nausea,vomiting,constipation symptoms improved significantly(P<0.05).Conclusions:1.Both treatments reduced the digital pain intensity scale(NRS)scores,and improve the KPS score and quality of life scale(EORTC QLQ-C30)score of patients with tumor bone metastatic cancer pain.2.The treatment group showed better than the experimental group in shortening the onset time of analgesic,prolonging the analgesic time,improving the KPS score and EORTC QLQ-C30 score,and alleviating adverse reactions.3.The treatment group can effectively improve the quality of life of patients with bone metastatic cancer pain,which means it is safe for clinical application.It can be further studied and popularized in the clinical treatment of cancer pain patients with metastatic bone tumor. |
PDF Full Text Request